(Q35047632)

6 August 2017

1 reference

title

The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma (English)

1 reference

6 August 2017

1 reference

Kyriaki Dunussi-Joannopoulos

series ordinal

1

1 reference

6 August 2017

publication date

1 November 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

43

1 reference

6 August 2017

issue

11

1 reference

6 August 2017

page(s)

2075-2082

1 reference

Current status and perspectives of therapy for acute myeloid leukemia

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Managing therapy in older adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

New cancer therapy by immunomanipulation: development of immunotherapy for human melanoma as a model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Genetic instabilities in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Genetic instability of cancer cells is proportional to their degree of aneuploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Costimulation of T cells for tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Manipulation of costimulatory signals to enhance antitumor T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Paracrine cytokine adjuvants in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Cytokines, tumour-cell death and immunogenicity: a question of choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Chemokines: agents for the immunotherapy of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Costimulation of T-cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The role of the CD28 receptor during T cell responses to antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The B7 and CD28 receptor families

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Models of T cell anergy: is there a common molecular mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

T-cell co-stimulation through B7RP-1 and ICOS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

CD28-B7 interactions in T-cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The role of CTLA-4 in the regulation and initiation of T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The emerging role of CTLA-4 as an immune attenuator

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

The treatment of acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

CHOP plus rituximab--balancing facts and opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000032926

10.1080/1042819021000032926

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference